Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 3 clinical ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online August 14 in ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Pembrolizumab, an anti–programmed death 1 (PD-1) monoclonal antibody, is a cornerstone of first-line standard care for recurrent and metastatic HNSCC. 1,2,7 The addition of pembrolizumab to ...

Pembrolizumab plus olaparib did not improve outcomes among patients with locally recurrent inoperable or metastatic triple-negative breast cancer, according to study results presented at San ...

Background: Treatment with the PD-1 inhibitor pembro produced significant improvement in disease-free survival after surgery for patients (pts) with ccRCC in the phase 3 KEYNOTE-564 trial. Based on ...

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.